Wnt dose escalation during the exit from pluripotency identifies tranilast as a regulator of cardiac mesoderm

Zhixuan Wu,Sophie Shen,Dalia Mizikovsky,Yuanzhao Cao,Marina Naval-Sanchez,Siew Zhuan Tan,Yanina D Alvarez,Yuliangzi Sun,Xiaoli Chen,Qiongyi Zhao,Daniel Kim,Pengyi Yang,Timothy A Hill,Alun Jones,David P Fairlie,Alice Pébay,Alex W Hewitt,Patrick P L Tam,Melanie D White,Christian M Nefzger,Nathan J Palpant,Yanina D. Alvarez,Timothy A. Hill,David P. Fairlie,Alex W. Hewitt,Patrick P.L. Tam,Melanie D. White,Christian M. Nefzger,Nathan J. Palpant
DOI: https://doi.org/10.1016/j.devcel.2024.01.019
IF: 13.417
2024-02-16
Developmental Cell
Abstract:Summary Wnt signaling is a critical determinant of cell lineage development. This study used Wnt dose-dependent induction programs to gain insights into molecular regulation of stem cell differentiation. We performed single-cell RNA sequencing of hiPSCs responding to a dose escalation protocol with Wnt agonist CHIR-99021 during the exit from pluripotency to identify cell types and genetic activity driven by Wnt stimulation. Results of activated gene sets and cell types were used to build a multiple regression model that predicts the efficiency of cardiomyocyte differentiation. Cross-referencing Wnt-associated gene expression profiles to the Connectivity Map database, we identified the small-molecule drug, tranilast. We found that tranilast synergistically activates Wnt signaling to promote cardiac lineage differentiation, which we validate by in vitro analysis of hiPSC differentiation and in vivo analysis of developing quail embryos. Our study provides an integrated workflow that links experimental datasets, prediction models, and small-molecule databases to identify drug-like compounds that control cell differentiation.
cell biology,developmental biology
What problem does this paper attempt to address?